Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer

Ahmed Mohieldin1 Medical Oncology, Zagazig University Hospitals, Zagazig, Egypt, [email protected];2 Medical Oncology Department, Sheikha Badriya Alsabah Centre, Kuwait Cancer Control Center, Shuwaikh, Kuwait

Ayman Rasmy1 Medical Oncology, Zagazig University Hospitals, Zagazig, Egypt, [email protected];3 Medical Oncology Department, King Saud Medical City, Riyadh, Saudi Arabia, [email protected];4 Medical Oncology Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia, [email protected]Correspondence[email protected]

Mohamed Ashour2 Medical Oncology Department, Sheikha Badriya Alsabah Centre, Kuwait Cancer Control Center, Shuwaikh, Kuwait;5 Clinical Oncology, Al-Azhar University, Cairo, Egypt

Muath Al-Nassar6 Thoracic Oncology – Sheikha Badriya Alsabah Centre, Kuwait Cancer Control Center, Shuwaikh, Kuwait

Rola H Ali7 Department of Pathology, Faculty of Medicine, Kuwait University, Safat, Kuwait;8 Molecular Laboratory, Kuwait Cancer Control Center, Shuwaikh, Kuwait

Fahad G El-Enezi6 Thoracic Oncology – Sheikha Badriya Alsabah Centre, Kuwait Cancer Control Center, Shuwaikh, Kuwait

Pages 6555-6561 | Published online: 29 Nov 2018

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

American Cancer Society’s Cancer Statistics Center [webpage on the Internet]Key Statistics for Lung Cancer2018 Available https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/key-statistics.htmlAccessed October 16, 2018
Google Scholar
KohnoTNakaokuTTsutaKBeyond ALK-RET, ROS1 and other oncogene fusions in lung cancerTransl Lung Cancer Res20154215625870798
PubMed Web of Science ®Google Scholar
LiTKungHJMackPCGandaraDRGenotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapiesJ Clin Oncol20133181039104923401433
PubMed Web of Science ®Google Scholar
CamidgeDRDoebeleRCTreating ALK-positive lung cancer--early successes and future challengesNat Rev Clin Oncol20129526827722473102
PubMed Web of Science ®Google Scholar
SodaMChoiYLEnomotoMIdentification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerNature2007448715356156617625570
PubMed Web of Science ®Google Scholar
MorrisSWKirsteinMNValentineMBFusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphomaScience19942635151128112848122112
PubMed Web of Science ®Google Scholar
ChenYTakitaJChoiYLOncogenic mutations of ALK kinase in neuroblastomaNature2008455721597197418923524
PubMed Web of Science ®Google Scholar
CoffinCMPatelAPerkinsSElenitoba-JohnsonKSPerlmanEGriffinCAALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumorMod Pathol200114656957611406658
PubMed Web of Science ®Google Scholar
ChristensenJGZouHYArangoMECytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphomaMol Cancer Ther2007612 Pt 13314332218089725
PubMed Web of Science ®Google Scholar
KazandjianDBlumenthalGMLuoLBenefit-risk summary of crizotinib for the treatment of patients with ROS1 alteration-positive, metastatic non-small cell lung cancerOncologist201621897498027328934
PubMed Web of Science ®Google Scholar
KhozinSBlumenthalGMZhangLFDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancerClin Cancer Res201521112436243925754348
PubMed Web of Science ®Google Scholar
LarkinsEBlumenthalGMChenHFDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following CrizotinibClin Cancer Res201622215171517627413075
PubMed Web of Science ®Google Scholar
MarkhamABrigatinib: First Global ApprovalDrugs201777101131113528597393
PubMed Web of Science ®Google Scholar
PetersSCamidgeDRShawATAlectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung CancerN Engl J Med2017377982983828586279
PubMed Web of Science ®Google Scholar
ShawATFribouletLLeshchinerIResensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198FN Engl J Med20163741546126698910
PubMed Web of Science ®Google Scholar
PazdurREndpoints for assessing drug activity in clinical trialsOncologist200813Suppl 2192118434634
PubMed Web of Science ®Google Scholar
TamaiKNagataKOtsukaKCrizotinib administered via nasogastric and percutaneous endoscopic gastrostomy tubes for the successful treatment of ALK-rearranged lung cancer in a patient with poor performance statusRespir Investig20135114648
PubMedGoogle Scholar
FerlayJSoerjomataramIDikshitRCancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012Int J Cancer20151365E3598625220842
PubMed Web of Science ®Google Scholar
SolomonBJMokTKimDWFirst-line crizotinib versus chemotherapy in ALK-positive lung cancerN Engl J Med2014371232167217725470694
PubMed Web of Science ®Google Scholar
BruynzeelAMLagerwaardFJWhole brain radiotherapy for brain metastases from non-small cell lung cancer: the end of an era?J Thorac Dis2016811E1525E152728066650
PubMed Web of Science ®Google Scholar
DoebeleRCPillingABAisnerDLMechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancerClin Cancer Res20121851472148222235099
PubMed Web of Science ®Google Scholar
ShawATYeapBYSolomonBJEffect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisLancet Oncol201112111004101221933749
PubMed Web of Science ®Google Scholar
LeeJOKimTMLeeSHAnaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancerJ Thorac Oncol2011691474148021642865
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date